Active transport of imatinib into and out of cells: implications for drug resistance.

By Julia Thomas, Lihui Wang, R. Clark, M. Pirmohamed. Blood, 2004

689 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/9b4e3caeac2cf7f7e5ebaaee16fd0b9446b8bb2b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Brian J. Druker
2. J. Cortes

In Hematology

1. Brian J. Druker
2. J. Cortes

Citations in the corpus

• Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. (2011, background): “Conversely, efficient imatinib uptake by leukemic stem cells may require expression of human organic cation transporter 1 (8, 16, 17).”
• Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (2007, neutral): “Median age, y (range) 59 (24-79) 59 (24-79) 59 (24-79)”